RVMD – revolution medicines, inc. (US:NASDAQ)

News

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer [Yahoo! Finance]
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer 
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Jefferies Highlights Revolution Medicines, Inc. (RVMD)'s RAS(ON) Platform in Coverage Initiation [Yahoo! Finance]
Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now? [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com